Skip to search formSkip to main contentSkip to account menu

Neovastat

Known as: Neovastat/AE-941 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AE-941Shark cartilage extract
GW786034

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Highly Cited
2004
Highly Cited
2004
Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue
A novel naturally occurring antiangiogenic agent isolated from cartilage, referred to as Neovastat (Æ-941), was examined for its… 
2004
2004
The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity
The plasminogen activator/plasmin system represents a key component of the proteolytic machinery underlying angiogenesis. In this… 
Highly Cited
2003
Highly Cited
2003
Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells.
Highly Cited
2003
Highly Cited
2003
Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer.
AE-941 (Neovastat), an antiangiogenic component extracted from cartilage, selectively competes for the binding of vascular… 
Highly Cited
2002
Highly Cited
2002
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
BACKGROUND renal cell carcinoma (RCC) is a potential target for anti-angiogenic drugs because of its high vascularization… 
Highly Cited
2002
Highly Cited
2002
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis.
Neovastat (AE-941), a naturally occurring multifunctional antiangiogenic agent, has been shown to inhibit key components of the… 
Highly Cited
2002
Highly Cited
2002
Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis.
There is considerable evidence to support an immunopathogenic basis of psoriasis. However, changes such as altered angiogenesis… 
Highly Cited
2002
Highly Cited
2002
The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model.
Bone metastases are generally associated with bone destruction which occurs in response to factors secreted by metastatic cells… 
Highly Cited
2002
Highly Cited
2002
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
PURPOSE Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, which exerts direct effects on vascular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License